Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

KalVista Pharmaceuticals (KALV) Change in Accured Expenses: 2013-2025

Historic Change in Accured Expenses for KalVista Pharmaceuticals (KALV) over the last 13 years, with Apr 2025 value amounting to $14.4 million.

  • KalVista Pharmaceuticals' Change in Accured Expenses rose 433.26% to $8.1 million in Q2 2025 from the same period last year, while for Apr 2025 it was $8.9 million, marking a year-over-year increase of 178.62%. This contributed to the annual value of $14.4 million for FY2025, which is 349.64% up from last year.
  • According to the latest figures from FY2025, KalVista Pharmaceuticals' Change in Accured Expenses is $14.4 million, which was up 349.64% from $3.2 million recorded in FY2024.
  • Over the past 5 years, KalVista Pharmaceuticals' Change in Accured Expenses peaked at $14.4 million during FY2025, and registered a low of $472,000 during FY2022.
  • Over the past 3 years, KalVista Pharmaceuticals' median Change in Accured Expenses value was $3.2 million (recorded in 2024), while the average stood at $6.5 million.
  • Per our database at Business Quant, KalVista Pharmaceuticals' Change in Accured Expenses spiked by 2,147.92% in 2021 and then slumped by 51.98% in 2022.
  • Yearly analysis of 5 years shows KalVista Pharmaceuticals' Change in Accured Expenses stood at $983,000 in 2021, then tumbled by 51.98% to $472,000 in 2022, then spiked by 309.32% to $1.9 million in 2023, then soared by 66.10% to $3.2 million in 2024, then soared by 349.64% to $14.4 million in 2025.